Orchid Pharma Limited · NSE:ORCHPHARMA

Orchid Pharma — Q3 FY2024-25 Earnings Presentation

10 slides from Orchid Pharma's earnings presentation, Feb 12, 2025

  1. Slide 1: Exchange intimation: Investors Presentation Q3 FY2024-25

    February 12, 2025 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: (i) Regulation 30 of Securities and Exchange Board of India (

  2. Slide 2: Financials Q3 & 9M-FY2024-25

    Orchid Pharma Limited Financials Q3 & 9M-FY2024-25 • All results in Standalone basis. • These are approx. nos. for exact nos. pls refer financials.

  3. Slide 3: Financial Highlights QTR-3 9M-25

    Financial Highlights QTR-3 9M-25 -2% +14% -14% +16% -23% +26% -23% +26%

  4. Slide 4: Financial Performance Including AMS

    Financial Performance Including AMS 12M-31st (Amt. in Cr.) Q3-2025 Q3-2024 Change % 9M-2025 9M-2024 Change % Mar’24 Sales 217 221 -2% 684 602 14% 819 Other Income 10 7 43% 26 18 44% 30 COGS 124 122 2% 406 356 14% 485 Employee Exp 22 19 16% 64 52 23% 70 Other Exp 44 44 0% 125 112 12% 155 EBITDA* 37 4

  5. Slide 5: AMS-Division Financial Performance

    AMS-Division Financial Performance (Amt. in Lacs) Q3-2025 9M-2025 Sales 33 92 Other Income 0 0 COGS 21 53 Employee Exp 207 511 Other Exp 94 166 EBITDA -289 -638

  6. Slide 6: Turnover (Amt. in Cr.)

    Turnover (Amt. in Cr.) 750 700 684 650 602 600 550 500 456 450 400 377 350 316 300 9M-21 9M-22 9M-23 9M-24 9M-25

  7. Slide 7: EBIDTA, PBT & PAT as % to Sales 9M-25

    EBIDTA, PBT & PAT as % to Sales 9M-25 20% 16% 16% 17% 15% 14% 9% 10% 10% 11% 5% 0% -5% -2% -10% -15% -14% -20% -25% -23% 9M-21 9M-22 9M-23 9M-24 9M-25 EBITDA PBT & PAT

  8. Slide 8: P&L Analysis – Gross Margin % to 9M Sales

    P&L Analysis – Gross Margin % to 9M Sales 60% 55% 54% 50% 45% 44% 42% 41% 41% 40% 35% 30% 9M-21 9M-22 9M-23 9M-24 9M-25

  9. Slide 9: P&L Analysis – Exp. % to Sales M9-25

    P&L Analysis – Exp. % to Sales M9-25 25% 23% 24% 21% 20% 19% 18% 16% 15% 12% 11% 10% 9% 9% 5% 9M-21 9M-22 9M-23 9M-24 9M-25 Emp Benefit Other Exp

  10. Slide 10: Thank You

    Thank You

Orchid Pharma — Q3 FY2024-25 Earnings Presentation on 6ix